Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)

BACKGROUND: Maraviroc (MVC) is a candidate for human immunodeficiency virus (HIV) pre-exposure prophylaxis. METHODS: Phase 2 48-week safety/tolerability study was conducted, comparing 4 regimens: MVC alone, MVC plus emtricitabine (FTC), MVC plus tenofovir disoproxil fumarate (TDF), and TDF plus FTC....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Infect Dis
Main Authors: Gulick, Roy M., Wilkin, Timothy J., Chen, Ying Q., Landovitz, Raphael J., Amico, K. Rivet, Young, Alicia M., Richardson, Paul, Marzinke, Mark A., Hendrix, Craig W., Eshleman, Susan H., McGowan, Ian, Cottle, Leslie M., Andrade, Adriana, Marcus, Cheryl, Klingman, Karin L., Chege, Wairimu, Rinehart, Alex R., Rooney, James F., Andrew, Philip, Salata, Robert A., Magnus, Manya, Farley, Jason E., Liu, Albert, Frank, Ian, Ho, Ken, Santana, Jorge, Stekler, Joanne D., McCauley, Marybeth, Mayer, Kenneth H.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Major Articles and Brief Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5790146/
https://ncbi.nlm.nih.gov/pubmed/27811319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiw525
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados